Mass production of the vaccine is expected to start in September 2020.
RDIF finances the production of the Sputnik V in Russia on the basis of production capacities of its portfolio companies, R-Pharm and Binnopharm, a part of the Alium Group.
RDIF sees strong global interest in the vaccine and plans to conduct Phase 3 clinical trials in different countries, including Saudi Arabia, UAE, Brazil and the Philippines, and start mass production in other countries in partnership with local sovereign wealth funds, including India, South Korea and Brazil, as well as, in Saudi Arabia, Turkey and Cuba.
The plan is to ramp up the vaccine production to 200 million doses by the end of 2020 including 30 million doses in Russia.
At least 20 countries had expressed interest in obtaining the Sputnik V, including UAE, Saudi Arabia, Indonesia, the Philippines, Brazil, Mexico and India.
Message has been successfully sent!